Abiopharma

🔍 Miller Taryn L (Executive)

Company: WOLVERINE WORLD WIDE INC /DE/ (WWW)

Report Date: 2026-05-10

Detailed Transactions and Holdings:

• Acquired 5,930 shares of Common Stock (Direct)
  Date: 2026-05-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,770.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,571 shares of Common Stock at $16.7 per share (Direct)
  Date: 2026-05-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 43,199.00 | transaction_form_type: 4
• Acquired 7,413 shares of Common Stock (Direct)
  Date: 2026-05-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 50,612.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,214 shares of Common Stock at $16.7 per share (Direct)
  Date: 2026-05-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 47,398.00 | transaction_form_type: 4
• Sold 5,930 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,930.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 7,413 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-10 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Restricted stock units convert into shares of Common Stock on a one-for-one basis.
• F2: On May 10, 2024, the Reporting Person was granted 17,791 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment; one-third on each of the first, second, and third year anniversaries of the grant date.
• F3: On May 10, 2024, the Reporting Person was granted 14,826 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment; 50% on each of the first and second year anniversaries of the grant date.